For inquiries or customized services, please reach us at pr@pharmaceutical-era.com
Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™...
Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy...
Pharmacy costs are consuming a growing share of employer healthcare budgets, but high drug prices and opaque contracts do not explain the entire problem. Employers continue to face spending above...
Triquetra Health, a clinical-grade supplement company specializing in evidence-based formulation, announced the launch of BioActive Vitamin B1™ Clinical Strength, a complete B1 activation system...
Today, resbiotic® the physician-developed microbiome health company headquartered in Dallas, Texas, announced the launch of two of its science-backed microbiome formulas — resB® Lung Support...
US Capital Global Securities LLC, the SEC-registered broker-dealer affiliate of the global financial group US Capital Global, is pleased to present eligible investors with the opportunity to...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is...
BD a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a...
Excedr, Inc. a leading provider of full-service laboratory equipment leasing solutions for the life sciences and healthcare industries, announced the closing of $25 million in growth capital.
InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs,...
Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay.
Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the...
